Integrated clinical development products and services provider Phesi has filed a new patent covering its smart technology that enables precise clinical trial planning and execution.
The enhanced technology, which is an integrated clinical trial design and protocol optimisation platform, enables Phesi’s systems to synthesise global patient data.
It also allows the company to assess baseline patient characteristics for clinical trial protocols.
Phesi founder and CEO Gen Li said: “Phesi’s business model has always been based on providing superior tech and data-enabled clinical development products and services.
“This patent filing is the final key to unlocking the potential for biopharmaceutical companies to change the future of clinical programmes, as the technology is informed by real patient data from comparable trials.
“In addition to reducing the need for post-hoc trial amendments, our integrated platform pinpoints patient populations of any size, type, and location, including for rare diseases.”
The enhanced technology features natural language processing and artificial intelligence (AI). It allows drug developers to optimise the design of their clinical trials and reduce the future risks associated with expensive protocol amendments.
FasterCures board member Annalisa Jenkins said: “It is exciting to see how Phesi’s smart technology is improving the productivity and efficiency of clinical research with operational enhancements that fundamentally shift drug development into a higher gear of effectiveness.
“Most importantly, this proprietary technology allows drug companies to expedite delivery of new treatment options to patients in need, leaving no excuse for poorly designed protocols and/or flawed operational planning.”
In July last year, Phesi launched self-service AI-powered tool ClinSite.